JP2014508784A5 - - Google Patents

Download PDF

Info

Publication number
JP2014508784A5
JP2014508784A5 JP2014500216A JP2014500216A JP2014508784A5 JP 2014508784 A5 JP2014508784 A5 JP 2014508784A5 JP 2014500216 A JP2014500216 A JP 2014500216A JP 2014500216 A JP2014500216 A JP 2014500216A JP 2014508784 A5 JP2014508784 A5 JP 2014508784A5
Authority
JP
Japan
Prior art keywords
treatment
radiolabeled compound
cancer
radioactive imaging
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014500216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014508784A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2012/000316 external-priority patent/WO2012129673A1/en
Publication of JP2014508784A publication Critical patent/JP2014508784A/ja
Publication of JP2014508784A5 publication Critical patent/JP2014508784A5/ja
Withdrawn legal-status Critical Current

Links

JP2014500216A 2011-03-25 2012-03-26 １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤 Withdrawn JP2014508784A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161467764P 2011-03-25 2011-03-25
US61/467,764 2011-03-25
PCT/CA2012/000316 WO2012129673A1 (en) 2011-03-25 2012-03-26 INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017253315A Division JP6727184B2 (ja) 2011-03-25 2017-12-28 １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤

Publications (2)

Publication Number Publication Date
JP2014508784A JP2014508784A (ja) 2014-04-10
JP2014508784A5 true JP2014508784A5 (cg-RX-API-DMAC7.html) 2016-10-27

Family

ID=46929260

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014500216A Withdrawn JP2014508784A (ja) 2011-03-25 2012-03-26 １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤
JP2017253315A Expired - Fee Related JP6727184B2 (ja) 2011-03-25 2017-12-28 １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017253315A Expired - Fee Related JP6727184B2 (ja) 2011-03-25 2017-12-28 １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤

Country Status (6)

Country Link
US (1) US11072632B2 (cg-RX-API-DMAC7.html)
EP (1) EP2688901B1 (cg-RX-API-DMAC7.html)
JP (2) JP2014508784A (cg-RX-API-DMAC7.html)
AU (1) AU2012234682A1 (cg-RX-API-DMAC7.html)
CA (1) CA2830984C (cg-RX-API-DMAC7.html)
WO (1) WO2012129673A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR096728A1 (es) * 2013-06-25 2016-01-27 Forendo Pharma Ltd Derivados de estratrieno-tiazol terapéuticamente activos
US9850272B2 (en) 2013-06-25 2017-12-26 Forendo Pharma Ltd. Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1
EP3139923B1 (en) * 2014-05-09 2023-09-27 Tangent Reprofiling Limited Composition for treating pancreatic adenocarcinoma
WO2016037956A1 (en) * 2014-09-11 2016-03-17 Bayer Pharma Aktiengesellschaft 3-nitrogen or sulphur substituted oestra-1,3,5(10),16-tetraene akr1c3 inhibitors
CZ307437B6 (cs) 2016-06-07 2018-08-22 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz
UA126342C2 (uk) * 2017-06-08 2022-09-21 Форендо Фарма Лтд 15-бета-[3-пропанамідо]-заміщені естра-1,3,5(10)-трієн-17-он-сполуки і їх 17-оксими для використання в інгібуванні 17-бета-гідроксистероїддегідрогеназ
WO2024020520A2 (en) * 2022-07-20 2024-01-25 Board Of Regents, The University Of Texas System Enzyme compositions, steroid derivatives, enzyme inhibitors, and methods of making same for pharmaceutical applications
AR133544A1 (es) * 2023-08-15 2025-10-08 Univ Laval INHIBIDORES IRREVERSIBLES DE 17b-HSD1

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
ATE209919T1 (de) 1987-09-24 2001-12-15 Jencap Res Ltd Oestrogen und progestin enthaltende verhütungspackungen
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5952319A (en) * 1997-11-26 1999-09-14 Research Triangle Institute Androgenic steroid compounds and a method of making and using the same
US6933312B2 (en) * 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
TWI331154B (en) 2003-11-12 2010-10-01 Solvay Pharm Gmbh Novel 17-hydroxysteroid dehydrogenase type i inhibitors
ES2388297T3 (es) 2005-05-26 2012-10-11 Abbott Products Gmbh Inhibidores de 17-HSD1 y STS
US10174070B2 (en) * 2005-09-30 2019-01-08 Endece Llc 6-substituted estradiol derivatives and methods of use
MX2009002579A (es) * 2006-09-19 2009-03-20 Solvay Pharm Gmbh Derivados de estratrieno y sus usos como inhibidores de 17beta-hidroxiesteroide deshidrogenasa.
MX2009005201A (es) * 2006-11-30 2009-05-27 Solvay Pharm Gmbh Derivados de estratrieno sustituidos como inhibidores de 17beta hsd.
WO2008089093A2 (en) 2007-01-12 2008-07-24 Quatrx Pharmaceuticals Company Efficient processes for preparing steroids and vitamin d derivatives with the unnatural configuration at c20 (20 alpha-methyl) from pregnenolone
EP2014672A1 (en) * 2007-07-12 2009-01-14 Bayer Schering Pharma Aktiengesellschaft 8-beta-substituted estratrienes as selectively active estrogens

Similar Documents

Publication Publication Date Title
IL268974B (en) Labeled inhibitors of prostate-specific membrane antigen (psma), their use as imaging agents and as pharmaceutical agents for the treatment of prostate cancer
PL3725810T3 (pl) Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu złośliwego
JP2014508784A5 (cg-RX-API-DMAC7.html)
IL235607A0 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
LT3319993T (lt) Axl specifiniai antikūno-vaistokonjugatai, skirti vėžiui gydyti
EA201400178A1 (ru) Лечение рака молочной железы
HUE043463T2 (hu) Vírusszerû részecske konjugátumok tumorok kezelésére
HUE036872T2 (hu) Kiméra, antigénreceptor-módosított T-sejt alkalmazása rák kezelésére
HUE047198T2 (hu) Fitokannabinoidok emlõrák kezelésére
ZA201706402B (en) C.novyi for the treatment of solid tumors in humans
HRP20180670T1 (hr) Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka
PT3053578T (pt) Terapêutica de combinação de cancro usando composto de azabiciclo
IL242546A0 (en) New compounds for cancer treatment
IL245551A0 (en) Anti-matriptase antibodies for cancer treatment
DK2802351T3 (da) Midler til behandling af triple-negativ brystkræft
PL2984108T3 (pl) Przeciwciała anty s100a7 do leczenia i diagnozowania nowotworu
SG11201506407VA (en) Kit for tumor imaging
IL237976A0 (en) A derivative of 7-azaindole-2,7-naphthyridine for the treatment of tumors
IL245477A0 (en) Diagnosis of lung cancer
SG11201911602RA (en) 18f-labelled compound for prostate cancer diagnosis, and use thereof
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
JP2012092693A5 (cg-RX-API-DMAC7.html)